SCHEDULE: Montanova Capital and Affiliates Adjust Veradermics Stake

Montanova Capital, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen have filed an amendment to their Schedule 13D, reporting changes in their beneficial ownership of Veradermics, Incorporated common stock.

Summary

• This filing is an amendment to a Schedule 13D, reporting changes in beneficial ownership of Veradermics, Incorporated common stock by Montanova Capital, LLC, Averill Master Fund, Ltd., Averill Madison Master Fund, Ltd., and Aaron Cowen.
• The reporting persons collectively hold 8.8% of Veradermics' common stock, based on 41,780,136 shares outstanding as of June 30, 2026, plus 300,000 shares from pre-funded warrants.
• On August 19, 2026, Averill Master Fund sold 690,601 shares and Averill Madison Master Fund sold 59,399 shares in open market transactions at $107.25 per share.
• On August 20, 2026, Averill Master Fund exercised pre-funded warrants for 149,000 shares and Averill Madison Master Fund exercised pre-funded warrants for 151,000 shares at $0.00001 per share, funded by working capital.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing as slightly negative due to the significant sale of shares by reporting persons, indicating a potential lack of confidence or a strategic shift, despite the exercise of warrants.

Positives

• The exercise of pre-funded warrants indicates continued investment or commitment to holding a position in the company, albeit at a nominal cost for the shares themselves.
• The reporting persons collectively still hold a significant stake of 8.8% in Veradermics, Incorporated.

Negatives

• Significant open market sales of Veradermics' common stock by Averill Master Fund (690,601 shares) and Averill Madison Master Fund (59,399 shares) on August 19, 2026, at $107.25 per share.
• The aggregate beneficial ownership percentage has decreased due to these sales.

Risks

• The open market sales by reporting persons could signal a reduction in their confidence in the company's near-term prospects or a strategic reallocation of capital.
• Further sales by these significant holders could exert downward pressure on the stock price.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. The actions reported are historical transactions.

Management Comments

• Mr. Cowen disclaims beneficial ownership of all shares of Common Stock held by the Funds, other than, to the extent of any pecuniary interest therein.
• Neither the filing of this Schedule 13D nor any of its contents shall be deemed to constitute an admission that any Reporting Person or any of its affiliates is the beneficial owner of any shares of Common Stock for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended, or for any other purpose.

Industry Context

StockSavvy.ai notes that Schedule 13D filings are typically made by investors who acquire a significant stake (over 5%) in a public company. Amendments often signal changes in ownership, strategy, or activist intentions. The reported sales and warrant exercises suggest a dynamic position held by these investment funds.

Stakeholder Impact

• Shareholders may be concerned by the significant share sales, potentially leading to increased stock price volatility or a negative sentiment.
• The warrant exercises, while nominal in cost per share, suggest a continued, albeit potentially reduced, interest from the reporting persons.

Next Steps

• The reporting persons may continue to buy or sell shares of Veradermics' common stock.
• Further amendments to Schedule 13D will be filed if ownership levels change significantly.

Key Dates

Recommendation

The filing indicates significant selling activity by major holders, which is a negative signal. However, these holders also exercised warrants, suggesting some continued interest. The net effect is mixed, warranting a 'hold' recommendation until further clarity on the reporting persons' intentions or company performance emerges.

Keywords

Schedule 13D, Beneficial Ownership, Veradermics, Montanova Capital, Averill Master Fund, Averill Madison Master Fund, Aaron Cowen, Stock Sale